title: [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
abstract: The study included 95 female patients of 65 to 74 years (average age 67,1 years), who previously (more than 6 months before this study) took a course of monotherapy with hydrochloride trospium in higher dosages with unstable or weak effect. In this study, all patients were divided into three groups and were treated with two antimuscarinic drugs. The majority of older women suffering from OAB and treatment-resistant taking one antimuscarinic drug in high doses showed a significant positive progress in a state by adding a second antimuscarinic agent. The received side effects do not exceed thereof in comparison with treatment with a single drug.
authors: Far Eastern University, Vladivostok, Russian Federation
authors: K V
authors: KV
authors: Kosilov
authors: Department of Urology, City Hospital No. 3, Vladivostok, Russian Federation
authors: S A
authors: SA
authors: Loparev
authors: Far Eastern National Fisheries University, Vladivostok, Russian Federation
authors: M A
authors: MA
authors: Krasnykh
authors: Medical Association No. 2 of Vladivostok, Vladivostok, Russian Federation
authors: L V
authors: LV
authors: Kosilova
mesh_terms: D000368:Aged; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000009:adverse effects; D001561:Benzilates / Q000008:administration & dosage / Q000009:adverse effects; D003408:Cresols / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D016903:Drug Monitoring; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage / Q000009:adverse effects; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000009:adverse effects; D009662:Nortropanes / Q000008:administration & dosage / Q000009:adverse effects; D010665:Phenylpropanolamine / Q000008:administration & dosage / Q000009:adverse effects; D011812:Quinuclidines / Q000008:administration & dosage / Q000009:adverse effects; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D053202:Urinary Incontinence, Urge / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D001559:Benzhydryl Compounds; D001561:Benzilates; D003408:Cresols; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D009662:Nortropanes; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; C003330:trospium chloride; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; C005419:oxybutynin; D000069464:Solifenacin Succinate